Innovative bioconjugation methods for the efficient detection of ovarian cancer at early stage

Abstract

Ovarian cancer (OC) is one of the most common cancer types in woman. OC can be successfully treated if detected early but the diagnosis of OC at early stages is difficult since there are no obvious symptoms and no screening test has proven to be effective. Several biomarkers have been identified for the diagnosis and therapy of ovarian carcinomas. However, the selectivity and sensitivity of the biomarkers dedicated to OC are still insufficient for the detection at early stages and for monitoring the treatment of the disease, we attempt to develop more efficient biosensor detection strategies based on the bioconjugation between nanobodies and the biomarkers.